Akeso

This phase 2 trial tests a new drug called AK146D1, given together with other cancer drugs, in 348 people with advanced non-small cell lung cancer that cannot be surgically removed. The study aims to see if the combination is safe and can shrink tumors. Participants will receive …

This study tests a new drug called AK146D1, given alone or with another drug (AK112), in people with advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if the treatment is safe and can shrink tumors. About 132 adults aged 18-75 with measurable tumors and…

This early-stage trial tests a new drug, AK138D1, alone or with another drug (ivonescimab) in people with advanced non-small cell lung cancer. The goal is to see if the treatment is safe and shrinks tumors. About 265 adults aged 18-75 with stage IIIB/IV cancer will take part.

This study tests two experimental drugs, AK146D1 and AK112, given together to people with advanced breast cancer that has spread or come back. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 200 adults aged 18 to 75 with HER2-negativ…

This early-stage trial tests a new drug called AK150 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors.

This study tests a new drug called AK138D1, given alone or with another drug (ivonescimab), in people with advanced breast cancer. The goal is to see if the treatment is safe and can shrink tumors. About 286 adults aged 18 to 75 will take part. This is an early-stage trial, so th…

This Phase 2 study tests a new biologic drug called AK139 in 168 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. Participants will receive either AK139 or a placebo by injection. The study aims to see if AK139 can safely clear skin and …

This study compares two ways of giving the immunotherapy drug AK104 alongside standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. One group gets AK104 as a shot under the skin (subcutaneous), the other as a…

This Phase 2 study tests a new drug called AK139 in 160 people with moderate to severe asthma. Participants receive either AK139 or a placebo by injection under the skin. The trial measures changes in lung function and asthma control over time, while also checking for side effect…

This study tests a combination of two experimental treatments—AK112 (given through a vein) and VG2025 (injected directly into liver tumors)—in 72 adults with advanced colorectal cancer that has spread to the liver and hasn't responded to prior therapy. The goal is to see if the c…

This Phase 1 trial tests a new drug called AK152 in healthy volunteers and people with Alzheimer's disease. The main goal is to check if it is safe and tolerable, and to see how the body processes it. The study is small and early-stage, so it will not prove whether the drug works…

This study tests a drug called AK112 in 60 people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has specific genetic changes and has stopped responding to previous targeted therapy. The main goal is to see how many patients' tumors shr…

This study tests a new medicine called AK139 for people with moderate to severe seasonal allergic rhinitis (hay fever). About 111 adults aged 18-65 with at least a 2-year history of seasonal allergies will receive either AK139 or a placebo. The main goal is to see if AK139 reduce…

This study checks whether AK104, an experimental cancer drug, behaves the same in the body when made at a new manufacturing site versus the original site. It involves 158 healthy Chinese men who will get a single low dose of the drug. The goal is to compare drug levels in the blo…